Enantioselective heterocyclic synthesis of spiro chromanone–thiochroman complexes catalyzed by a bifunctional indane catalyst
作者:Yaojun Gao、Qiao Ren、Hao Wu、Maoguo Li、Jian Wang
DOI:10.1039/c0cc03489d
日期:——
benzylidenechroman-4-ones and 2-mercaptobenzaldehydes for efficient construction of spiro chromanone-thiochroman complexes were accomplished with high yields and excellent selectivities via a novel bifunctional indane catalyst.
Substituted benzopyran analogs for the treatment of inflammation
申请人:G.D. Searle & Co.
公开号:US06077850A1
公开(公告)日:2000-06-20
A class of benzopyrans, benzothiopyrans, dihydroquinolines, dihydronaphthalenes, and analogs thereof, is described for use in treating cyclooxygenase-2 mediated disorders. Compounds of particular interest are defined by Formula I'wherein X, A.sup.1, A.sup.2, A.sup.3, A.sup.4, R, R", R.sup.1 and R.sup.2 are as described in the specification.
Substituted benzopyran derivatives for the treatment of inflammation
申请人:G.D. Searle & Co.
公开号:US06034256A1
公开(公告)日:2000-03-07
A class of benzopyran, derivatives is described for use in treating cyclooxygenase-2 mediated disorders. Compounds of particular interest are defined by Formula I' ##STR1## wherein X, A.sup.1, A.sup.2, A.sup.3, A.sup.4, R, R", R.sup.1 and R.sup.2 are as described in the specification.
Enantioselective Organocatalytic Tandem Michael−Aldol Reactions: One-Pot Synthesis of Chiral Thiochromenes
作者:Wei Wang、Hao Li、Jian Wang、Liansuo Zu
DOI:10.1021/ja063328m
日期:2006.8.1
A highly enantioselective (S) diphenylpyrrolinol silyl ether promoted tandem Michael-aldol reaction of alpha,beta-unsaturated aldehydes with 2-mercaptobenzaldehydes has been developed. The method affords one-pot access to chiral and synthetically useful thiochromenes in high yields and high enantioselectivities from readily available compounds.
已开发出高度对映选择性 (S) 二苯基吡咯啉甲硅烷基醚促进 α、β-不饱和醛与 2-巯基苯甲醛的串联迈克尔-羟醛反应。该方法提供了从容易获得的化合物中以高产率和高对映选择性获得手性和合成有用的硫色素的一锅法。
Antiangiogenic combination therapy for the treatment of cancer
申请人:——
公开号:US20020103141A1
公开(公告)日:2002-08-01
The present invention provides combinations of a DNA topoisomerase I inhibiting agent and a selective COX-2 inhibiting agent for preventing, treating, and/or reducing the risk of developing a neoplasia disorder in a mammal.